德展健康(000813) - 2025 Q4 - 年度业绩预告

Financial Performance - The company expects a net profit loss between CNY 17,500,000 and CNY 35,000,000 for the fiscal year 2025, compared to a loss of CNY 2,041,310 in the same period last year[2] - The net profit loss after deducting non-recurring gains and losses is also projected to be between CNY 17,500,000 and CNY 35,000,000, compared to a loss of CNY 2,369,670 in the previous year[2] - Basic earnings per share are expected to be between CNY -0.0827 and CNY -0.1654, compared to a loss of CNY 0.0095 per share in the prior year[2] Business Focus and Strategy - The company is focusing on core biopharmaceutical business and technology innovation, with ongoing development of innovative drugs and the operation of a psychological rehabilitation hospital[4] - The anticipated losses are attributed to continued investment in nurturing business and R&D innovation, the impact of centralized procurement policies on revenue, and impairment provisions for long-term equity investments and goodwill[4]